Shots:
The P-III (SENTRY) trial assessed Selinexor (60mg, QW) + ruxolitinib vs PBO + ruxolitinib in 353 pts with frontline myelofibrosis; FDA discussions on SENTRY data & its sNDA strategy is underway, with potential compendia inclusion in H2’26
As of Feb 20, 2026, trial met its first co-1EP, with 50% vs 28% achieving SVR35 at…
Shots:
PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, China, and Korea. This month’s report includes 7 biological drugs, 10 small molecules, 8 cell and gene therapies, 1 radiopharmaceutical, 2 microbiota and 1 diagnostic test
MyoPax’ Satori-01, focused on repairing the Exstrophy-Epispadias Complex sphincter…

